November: 68 year-old man with a Stage IV Prostate cancer

case study breast cancer with hormone receptor HR positive

Case description:

Prostate cancer is the fifth leading cause of cancer death in the world. When the cancer is localized, it is usually indolent, with a 5-year survival rate of nearly 100%. However, when the tumor metastasizes, the 5-year survival rate decreases to 30% (PMID: 24384911). We describe the case of a 68 year-old man diagnosed with a Stage IV prostate cancer in 2019. He also presents metastases in the pelvis and left lung. He was treated with a combination of casodex, paclitaxel and carboplatin but eventually he stopped responding to the treatment. At the end of 2021 he had a prostate biopsy taken and decided to test the genomic profile of the tumor using our solution OncoDEEP® Kit.

Clinical interpretation and analysis results

Reducing androgen signalling

Around 85% of the cases of prostate cancer are androgen-dependent when they first get diagnosed. That’s why the first line of treatment for these patients aims to reduce androgen signalling trough androgen ablation therapy and the inhibition of Androgen Receptor (AR).
 
AR is a receptor that binds the Androgen hormone in the cytoplasm of the cells. Upon hormone perception, the receptor gets translocated into the nucleus and regulates the transcription of androgen responsive genes. These genes affect cellular proliferation and differentiation in target tissues (PMID: 23084523; PMID: 18301781) and are involved in cell cycle control and migration (PMID: 24384911). The importance of this gene in prostate cancer development is well known, since AR overexpression is common in prostate cancer, causing hormone independent activation of effector genes and stimulated prostate growth (PMID: 16598769; PMID: 12970746) – (Figure 1). AR mutations also appear in some prostate cancer in advanced stages (PMID: 8827083; PMID: 14501770).
 
However, the first line of treatments that reduce androgen signalling eventually stop working, and the great majority of patients experience progression, and the tumor becomes castration-resistant (PMID: 24384911). In this case, the patient followed a first line of treatment with a combination of an antiandrogen hormonotherapy (casodex) and two chemotherapies (paclitaxel and carboplatin). Casodex is a synthetic, nonsteroidal antiandrogen. The drug competitively binds to AR in target tissues, thereby inhibiting the receptor binding of androgen. Remarkably, casodex does not bind to most mutated forms of AR.
 

Figure 1: Mechanism of action and resistance of AR inhibitors in prostate cancer

Unravelling AR inhibition resistance

A T878A variant was found in the (AR) gene. In fact, variant T878A in AR is located in the ligand binding domain of AR and alters the binding properties of the receptor. The onset of this mutation during the progression of the illness could explain the eventual resistance to the casodex treatment of the patient, since the modification of the binding domain of AR would impair the binding of casodex to AR, preventing its therapeutic effect.

Variant T878A has been reported to confer resistance to abiraterone therapy (PMID: 27148695; PMID: 25712683; PMID: 26537258; PMID: 26067250, PMID: 25320358) and decreased response to enzalutamide and apalutamide, small AR antagonists (PMID: 27148695; PMID: 22334387; PMID: 30425524). That is why this patient should not be sensitive to AR inhibitors, such as the androgen biosynthesis inhibitor abiraterone acetate, the AR antagonists apalutamide, bicalutamide and enzalutamide.

Nevertheless, T878A may not cause resistance to all antiandrogens, since preclinical data showed that darolutamide, a new oral AR antagonist, is able to significantly inhibit the transcriptional activity of T878A (PMID: 28851578). Darolutamide is FDA approved and indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer in combination with docetaxel. Interestingly, there is a clinical trial (NCT03385655) that enrols patients of prostate cancer that present DNA abnormalities.As well, proxalutamide is another AR antagonist with potential antineoplastic activity. Nowadays, there is an interesting Phase II clinical trial (NCT03899467) that recruits patients with metastatic castrate resistant prostate cancer who progressed after either abiraterone or enzalutamide therapies.

To note, OncoDEEP® Kit analysis was able to identify an AR variant linked to therapy resistance and the potential cause of relapse of the patient to AR inhibition. More importantly, the molecular profile of the tumor is critical to gather information on the sensitivity and resistance to approved targeted treatments, immunotherapies and hormone therapy, as well as finding interesting clinical trials for the patient. This knowledge can help guiding future personalised clinical decisions adapted to the molecular characteristics of each patient.

Identifiyng new therapeutical options

A variant in the ARID1A gene inducing a probable loss of function of the protein was present in the patient. ARID1A is an helicase that regulates the transcription of certain genes by altering the adjacent chromatin structure. In cancer, ARID1A is a tumor suppressor gene, that is, a gene that prevents the formation of tumors. Therefore, mutations in this gene may alter his function and impair its anti-tumor effect. In fact, ARID1A has a high mutation frequency in bladder cancer, uterine endometrioid carcinoma, ovarian endometrioid and clear cell carcinoma.

Although there are no therapies targeting such loss of function, Ceralasertib (an ATR kinase inhibitor) is a drug under clinical development with potential antineoplastic activity. Currently, there is Phase II clinical trial that evaluates the effect of this  drug alone and in combination with olaparib in patients with various solid tumors, including prostate cancer (NCT03682289). One of the arms of this study recruits specifically with ARID1A alterations. What is more, loss of function in ARID1A gene has been associated with a higher tumor mutational burden (TMB, number of mutations per megabase on the DNA of the patient), and this is the case for this patient.

This patient presents high Microsatellite Instability (MSI) and tumor mutational burden (TMB) scores.
Outstandingly, we observed a high level of MSI, an hypermutable phenotype consisting in an alternative number of repetitions in microsatellite regions of the DNA. The phenotype is caused by the loss of DNA mismatch repair (MMR) activity (PMID: 20420947), which is associated with inactivation, loss or epigenetic silencing of MMR genes (MSH2, MLH1, MSH6 and PMS2).

Figure 2: Biomarkers driving immune response through PD-1/PD-L1 inhibition in prostate cancer

High MSI contributes to a high rate of somatic mutations in tumor cells, that leads to a variety of molecular changes, such as high TMB or increased expression of neoantigens in tumor cells. In fact, a recent study in almost 3000 samples demonstrates that high MSI is highly associated with the onset of the TMB phenotype in prostate cancer, since the majority of high TMB tumors are also MSI high (PMID: 37662703). Strikingly, only 5% of the patients of prostate cancer have high TMB. TMB is defined as the number of mutations per megabase on the DNA of the patient, and high TMB could lead to the clinical benefit of the immunotherapies (PD-1/PD-L1 inhibitors) in several cancers (PMID: 28835386), indicating that this patient could have a high potential response to immunotherapy (PD-1/PD-L1 inhibitors) (Figure 2).

In this sense, pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2. This way, it blocks the PD-1 pathway-mediated inhibition of the immune response, promoting the reactivation of the anti-tumor immune response. In fact, pembrolizumab has been approved for MSI-High solid tumors, and, in mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
 

All in all, OncoDEEP® Kit has uncovered that this patient falls in the rare subgroup of prostate cancer patients that present high TMB, and could benefit from immunotherapy (5%). Remarkably, only the NGS analysis of the tumor is able to unravel such veiled molecular phenotypes, providing new therapeutic options that could improve the patient’s treatment and that, otherwise, would never be accessible for him.

 

You may also be interested in these resources

Press Release

OncoDNA laboratory has received the CAP accreditation

Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...

Share This